Posted on

cbd structure

Structure CBD is comprised of a team of cannabis and natural health advocates who are educated and dedicated to the plant, in addition to an on-staff compound pharmacist. We believe in a healthcare based approach for the use of CBD. We select only the purest ingredients and use them to produce a pure, potent, and proven product.

At Structure CBD, we believe transparency and consistency should be put first and foremost when producing any product. All Structure CBD raw materials and finished products have been third party tested by an ISO-17025 accredited lab to ensure purity, potency, and safety prior to release. Structure products are backed by a 100% satisfaction guarantee.

Terpenes are organic compounds that are found throughout the plant kingdom, the precursors of essential oils. Terpenes heavily influence a plants scent and may be partly responsible for a plants therapeutic properties. Cannabinoids and Terpenes work in synergy together and some researchers believe that these compounds are crucial to the delivery of cannabinoids through the body.

Trusted Advocates

Curated Terpenes

Cbd structure

CB1R and CB2R interact with endogenous ligands including anandamides, which are arachidonic acid derivatives. The endogenous system modulates neuronal activity via cyclic-AMP, Ca 2+ transport, and K + ions, and is thought to be associated with opioid, GABAergic, dopaminergic, and several other systems. THC exerts its psychotropic effects via CB1R binding and downstream signaling.

RCTs investigating the effects of cannabis are limited, due in part to the legality of its use. However, there have been some randomized controlled trials examining the efficacy of smoked cannabis for various medical conditions:

The mechanism of action of THC vs CBD

As CBD does not produce a high, and does not associated with abuse or dependence potential, it is an appealing option for managing many medical conditions. Epidiolex, is a CBD oral solution that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with rare and severe forms of epilepsy (Lennox-Gastaut syndrome and Dravet syndrome) in young children. There are also many clinical trials underway to assess the effects of CBD for various medical conditions, including:

Several RCTs investigating the effects of CBD have been completed, including:

Randomized controlled trials investigating THC

Alternatively, CBD does not bind and stimulate the CB1 receptor, and therefore does not exert psychotropic effects. Recent evidence suggests CBD is a negative allosteric modulator of CB1R, preventing THC binding and stimulation. It has also been suggested that CBD may interact with the endocannabinoid system via indirect mechanisms including: inhibition of adenosine uptake, enhanced 5-HT1A receptor activity, enhanced activity at glycine receptor subtypes, among others.